Alyea E, Weller E, Schlossman R, Canning C, Webb I, Doss D, Mauch P, Marcus K, Fisher D, Freeman A, Parikh B, Gribben J, Soiffer R, Ritz J, Anderson K.  T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion with multiple myeloma: induction of graft-versus-myeloma effect.  Blood 2001; 98(4): 934-939.

 

Bernardo MVP, Harrington DP.  Sample-size calculations for the two-sample problem using the multiplicative intensity model.  Stat Med.  2001; 20:557-579.

 

Bonetti M, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Coates AS for the IBCSG. .  8. Innovative strategies of adjuvant treatments: Features that predict responsiveness to chemotherapy and endocrine therapies.  The Breast 2001; 10(3):147-157.

 

Brand KP, Catalano PJ, Hammitt JK, Rhomberg L, Evans JS.  Limitations to empirical extrapolation studies: the case of BMD ratios.  Risk Analysis.  2001; 21: 625-640.

 

Burstein HJ, Kuter I, Campos SM, Gelman RS, Tribou L, Parker LM, Manola J, Younger J, Matulonis U, Bunnell CA, Partridge AH, Richardson PG, Clarke K, Shulman LN, Winer EP.  Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer.  J Clin Oncol. 2001; 19(10): 2722-2730.

 

Colleoni M, Gelber S, Coates AS, Castiglione-Gertsch M, Gelber RD, Price K, Rudenstam C-M, Lindtner J, Collins J,  Thurlimann B, Holmberg SB, Cortes-Funes H, Simoncini E, Murray E, Fey M, Goldhirsch A.  Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer.  J Clin Oncol.  2001; 19(21): 4141-4149.

 

Chen M-H, Ibrahim JG.  Maximum likelihood methods for cure rate models with missing covariates.  Biometrics.  2001; 57:43-52.

 

Cole BF, Gelber RD, Gelber S, Coates AS, Goldhirsch A.   Polychemotherapy for early breast cancer: an overview of the randomized clinical trials with quality-adjusted survival analysis.  The Lancet.  2001; 358:277-286.

 

Colevas AD, Amrein PC, Gomolin H, Barton JJ, Read RR, Adak S, Benner S, Costello R, Posner MR.  A phase II study of combined oral uracil and ftorfur with Leucovorin for patients with squamous cell carcinoma of the head and neck.  Cancer.  2001; 92:326-31. 

 

Colleoni M, Gelber RD, Gelber S, Castiglione-Gertsch M, Coates AS, Goldhirsch A.  6. Adjuvant systemic therapies I: How to improve timing and duration of adjuvant chemotherapy.  The Breast 2001; 10(3):101-105.

 

Cook RJ, Brumback BB, Wigg MB, Ryan LM.  Synthesis of evidence from epidemiological studies with interval-censored exposure due to grouping.  Biometrics.  2001; 57:671-680.

 

Corcoran C, Ryan L, Senchaudhuri P, Mehta C, Patel N, Molenberghs G.  An exact trend test for correlated binary data.  Biometrics.  2001; 57:941-948.

 

Coull BA, Hobert JP, Ryan LM, Holmes LB.  Crossed random effect models for multiple outcomes in a study of teratogenesis.  J Am Stat Assoc 2001; 96(456):1194-1204.

 

Davidov O, Zelen M.  Referent sampling, family history and relative risk: the role of length-biased sampling. Biostatistics.  2001; 2(2):173-181.

 

Earle CC, Tsai JS, Gelber RD, Weinstein MC, Neumann PJ, Weeks JC.  Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis.  J Clin Oncol.  2001; 19(4): 1064-1070.

 

Fine JP, Gelber RD.  Joint regression analysis of survival and quality-adjusted survival.  Biometrics.  2001; 57:376-382.

 

Fitzmaurice GM, Lipsitz SR, Molenberghs G, Ibrahim JG.  Bias in estimating association parameters for longitudinal binary responses with drop-outs.  Biometrics.  2001; 57: 15-21.

 

Fonesca R, Oken MM, Harrington D, Bailey RJ, Van Wier SA, Henderson KJ, Kay NE, Van Ness B, Greipp PR, Dewald GW.  Deletions of chromosome 13 in multiple myeloma identified by interphase FISH usually denote large deletions of the q arm or monosomy.  Leukemia.  2001; 15: 981-986.

 

Forastiere AA, Leong T, Rowinsky E, Murphy BA, Vlock DR, DeConti RC, Adams GL.  Phase III comparison of high-dose paclitaxel + cisplatin + granulocyte colony-stimulating factor versus low-dose paclitaxel + cisplatin in advanced head and neck cancer: Eastern Cooperative Oncology Group Study E1393.  J Clin Oncol.  2001; 19(4): 1088-1095.

 

Friedberg JW, Neuberg D, Monson J, Fallow H, Nadler LM, Freedman AS.  The impact of external beam radiation therapy prior to autologous bone marrow transplantation in patients with non-Hodgkin=s lymphoma.  Biology of Blood and Marrow Transplantation.  2001; 7:446-453.

 

Frustaci S, Gherlinzoni F, DePaoli A, Bonetti M, Azzarelli A, Comandone A, Olmi P, Buonadonna A, Pignatti G, Barbieri E, Apice G, Zmerly H, Serraino D, Picci P.  Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian Randomized Cooperative Trial.  J Clin Oncol.  2001; 19(5): 1238-1247.

 

Gelber S, Coates AS, Goldhirsch A, Castiglione-Gertsch M, Marini G, Lindtner J, Edelmann DZ, Gudgeon A, Harvey V, Gelber RD (IBCSG).  Effect of pregnancy on overall survival after the diagnosis of early-stage breast cancer.  J Clin Oncol.  2001; 19(6): 1671-1675.

 

Geys H, Regan MM, Catalano PJ, Molenberghs G.  Two latent variable risk assessment approaches for mixed continuous and discrete outcomes from developmental toxicity data.  Journal of Agricultural, Biological, and Environmental Statistics.  2001; 6(3):340-355.

 

Goldhirsch A, Gelber RD, Yothers G, Gray RJ, Green S, Bryant J, Gelber S, Castiglione-Gertsch M, Coates AS.  Adjuvant therapy for very young women with breast cancer: need for tailored treatments.  J Natl Cancer Inst Monogr 2001; 30:44-51.

 

Goldhirsh A, Glick JH, Gelber RD, Coates AS, Senn HJ.  Meeting highlights: International consensus panel on the treatment of primary breast cancer.  J Clin Oncol.  2001; 19(18):3817-3827.

 

Gradishar WJ, Stephenson P, Glover DJ, Neuberg DS, Moore MR, Windschiti HE, Piel I, Abeloff MD.  A phase II trial of cisplatin plus WR-2721 (Amifostine) for Metastatic breast carcinoma: an Eastern Cooperative Oncology Group Study (E8188).  Cancer.   2001; 92:2517-2522.

 

Herring AH, Ibrahim JG.  Likelihood-based methods for missing covariates in the Cox proportional hazards model.  J Am Stat Assoc.  2001; 96(453):292-302.

 

Hochberg EP, Chillemi AC, Wu CJ, Neuberg D, Canning C, Hartman K, Alyea EP, Soiffer RJ, Kalams SA, Ritz J.  Quantitation of T-cell neogenesis in vivo after allogeneic bone marrow tansplantation in adults.  Blood.  2001; 98(4):1116-1121.

 

Ibrahim JG, Chen MH, Lipsitz SR.  Missing responses in generalised linear mixed models when the missing data mechanism is nonignorable.  Biometrika.  2001; 88(2):551-564.

 

Ibrahim JG, Chen M-H, Sinha D.  Criterion-based methods for Bayesian model assessment.  Statistica Sinica.  2001; 11(2): 419-443.

 

Ibrahim JG, Chen M-H, Sinha D.  Bayesian semiparametric models for survival data with a cure fraction.  Biometrics.  2001; 57:383-388.

 

Ibrahim JG, Lipsitz SR, Horton N.  Using auxiliary data for parameter estimation with non-ignorably missing outcomes.  Appl Statist.  2001; 50(30):361-373.

 

The International Breast Cancer Study Group (Writing Committee: B. Thurlimann, Price KN, Castiglione M, Coates AS, Goldhirsch A, Gelber RD, Forbes J, Holmberg S, Veronesi A, Bernhard J,  Zahrieh D).  7. Adjuvant systematic therapies: Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: is chemotherapy necessary for premenopausal women with node-positive, endocrine-responsive breast cancer: First results of International Breast Cancer Study Group Trial 11-93.  The Breast 2001; 10(3):130-138.

 

Jones CL, Harrington DP.  Omnibus tests of the martingale assumption in the analysis of recurrent failure time data.  Lifetime Data Analysis.  2001; 7:157-171.

 

Kirkwood JM, Ibrahim J, Lawson DH, Atkins MB, Agarwala SS, Collins K, Mascari R, Morrissey DM, Chapman PB.  High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the multicenter Eastern Cooperative Oncology Group Phase II Trial E2696.  J Clin Oncol.  2001; 19(5): 1430-1436.

 

Kirkwood JM, Ibrahim JG, Sasman JA, Sandak VK, Agarwala SS, Ernstoff MS, Rao U.  High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.  J Clin Oncol.  2001; 19(9): 2370-2380.

 

Legedza ATR, Ibrahim JG.  Heterogeneity in phase I clinical trials: prior elicitation and computation using the continual reassessment method.  Stat Med.  2001; 20:867-882.

 

Leong T, Lipsitz SR, Ibrahim JG.  Incomplete covariates in the Cox model with applications to biological marker data.  Appl Statist.  2001; 50:467-484.

 

Lipsitz S, Parzen M, Molenberghs G, Ibrahim J.  Testing for bias in weighted estimating equations.  Biostatistics.  2001; 2(3):295-307.

 

Loehrer PJ, Jiroutek M, Aisner S, Aisner J, Green M, Thomas CR, Livingston R, Johnson DH.  Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma.  Cancer.  2001; 91:2010-5.

 

Long CM, Suh HH, Kobzik L, Catalano PJ, Ning YY, Koutrakis P.  A pilot investigation of the relative toxicity of indoor and outdoor fine particles: in vitro effects of endotoxin and other particulate properties. Environ Health Perspec 2001; 109: 1019-1026.

 

Etemad-Moghadam B, Rhone D, Steenbeke T, Sun Y, Manola J, Gelman R, Fanton JW, Racz P, Tenner-Racz K, Axthelm MK, Letvin NL, Sodroski J.  Membrane-fusing capacity of the human immunodeficiency virus envelope proteins determines the efficiency of CD4+ t-cell depletion in Macaques infected by a simian-human immunodeficiency virus.  J Virol.  2001; 5646-5655.

 

Murphy BA, Leong T, Burkey B, Langer C, Forastiere A.  Lack of efficacy of topotecan in the treatment of metastatic or recurrent squamous carcinoma of the head and neck: an Eastern Cooperative Oncology Group Trial (E3373).  Am J Clin Oncol.  2001; 24(1): 64-66.

 

Mutter GL, Baak JPA, Path FRC, Fitzgerald JT, Gray R, Neuberg D, Kust GA, Gentleman R, Gullans, SR, Wei L-J, Wilcox.  Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation.  Gynecol Oncol.  2001; 83:177-185.

 

Nam CM, Zelen M.  Comparing the survival of two groups with an intermediate clinical event.  Lifetime Data Analysis.  2001; 7:5-19.

 

Obasaju C, Manola J, Hudes GR, Khandekar JD, Citrin DL, Carbone P, Trump DL.  Phase II evaluation of menogaril in advanced prostate cancer (Eastern Cooperative Oncology Group EST P-A885).  Am J Clin Oncol (CCT).  2001; 24(2): 150-154.

 

O’Dwyer PJ, Manola J, Valone FH, Ryan LM, Hines JD, Wadler S, Haller DG, Arbuck SG, Weiner LM, Mayer RJ, Benson A III.  Fluorouracil modulation in colorectal cancer: lack of improvement with N-Phosphonoaceytl-l-aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule C an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B study.  J Clin Oncol.  2001; 19(9): 2413-2421.

 

Oh WK, George DJ, Hackmann K, Manola J, Kantoll PW.  Activity of the herbal combination, PC-SPEC, in the treatment of patients with androgen-independent prostate cancer.  Urology.  2001; 57: 122-126.

 

Page DL, Gray R, Allred DC, Dressler LG, Hatfield AK, Martino S, Robert NJ, Wood WC.  Prediction of node-negative breast cancer outcome by histologic grading and s-phase analysis by flow cytometry: an Eastern Cooperative Oncology Group Study (2192).  Am J Clin Oncol.  2001; 24(1): 10-18.

 

Pandya KJ, Yeap BY, Weiner LM, Krook JE, Erban JK, Schinella RA, Davis TE.  Megestrol and tamoxifen in patient with advanced endometrial cancer (an Eastern Cooperative Oncology Group Study (E4882)).  Am J Clin Oncol.  2001; 24(1):43-46.

 

Parise H, Wand MP, Ruppert D, Ryan L.  Incorporation of historical controls using semiparametric mixed models.  Appl Statist.  2001; 50(1): 31-42.

Robins J, Rotnitzky A, Bonetti M.  Discussion of the Frangakis and Rubin article.  Biometrics.  2001; 57: 343-347.

 

Sarnat JA, Schwartz J, Catalano PJ, Suh HH.  Gaseous pollutants in particulate matter epidemiology: confounders or surrogates?  Environ Health Perspec 2001; 109:1053-1061.

 

Schiller JH, Adak S, Feins RH, Keller SM, Fry WA, Livingston RB, Hammond MEM, Wolf B, Sabatini L, Jett J, Kahman L, Johnson DH.  Lack of prognostic significance of p53 and K-ras mutations in primary resected non-small-cell lung cancer on E4592: a laboratory ancillary study on an Eastern Cooperative Oncology Group prospective randomized trial of postoperative adjuvant therapy.  J Clin Oncol.  2001; 19(2):448-457.

 

Schink JC, Weller E, Harris LS, Cella D, Gerstner J, Falkson C, Wadler S.  Outpatient taxol and carboplatin chemotherapy for suboptimally debulked epithelial carcinoma of the ovary results in improved quality of life: an Eastern Cooperative Oncology Group Phase II Study (E2E93).  The Cancer Journal.  2001; 7(2):155-164.

 

Schwartz CL, Thompson EB, Gelber RD, Young ML, Chilton D, Cohen HJ, Sallan SE.  Improved response with higher corticosteroid dose in children with acute lymphoblastic leukemia.  J Clin Oncol.  2001; 19(4):1040-1046.

 

Shapiro CL, Manola J, Leboff M.  Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer.  J Clin Oncol.  2001; 19(14):3306-3311.

 

Shen Y, Wu D, Zelen M.  Testing the independence of two diagnostic tests.  Biometrics 2001; 57:1009-1017.

 

Shen Y, Zelen M.  Screening sensitivity and sojourn time from breast cancer early detection clinical trials:  mammograms and physical examinations.  J Clin Oncol  2001; 19(15):3490-3499.

 

Soiffer RJ, Weller E, Alyea EP, Mauch P, Webb IL, Fisher DC, Freedman AS, Schlossman RL, Gribben J, Lee S, Anderson KC, Marcus K, Stone RM, Antin JH, Ritz J.  CD6+ donor marrow t-cell depletion as the sole form of graft-versus-host disease prophylaxis in patients undergoing allogeneic bone marrow transplant from unrelated donors.  J Clin Oncol.  2001; 19:1152-1159.

 

Sweeney CJ, Zhu J, Sandler AB, Schiller J, Belani CP, Langer C, Krook J, Harrington D, Johnson DH.  Outcome of patients with a performance status of 2 in Eastern Cooperative Oncology Group Study E1594.  Cancer.  2001; 92: 2639-2647.

 

Waber DP, Shapiro BL, Carpentieri SC, Gelber RD, Zou G, Dufresne A, Romero I, Tarbell NJ, Silverman LB, Sallan SE.  Excellent therapeutic efficacy and minimal late neurotoxicity in children treated with 18 grays of cranial radiation therapy for high-risk acute lymphoblastic leukemia.  Cancer.  2001; 92: 15-22.

 

Wallace SR, Oken MM, Lunetta KL, Panoskaltsis-Mortari A, Masellis AM.  Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients.  Cancer.  2001; 91(7):1219-1230.

 

Watanabe T, Wu T-T, Catalano PJ, Ueki T, Satriano R, Haller DG, Benson AB, Hamilton SR.  Molecular predictors of survival after adjuvant chemotherapy for colon cancer.  N Engl J Med.  2001; 344:1196-1206.

 

Wiernik PH, Leong T, Oken MM, Neiman RS, Habermann TM, Bennett JM, Schuster S, Glick JH.  Bleomycin, lomustine, cyclophosphamide, vincristine, procarbazine and prednisone (BLEO-CCVPP) in patients with Hodgkin's disease who relapsed after radiotherapy alone: a long-term follow-up study of the Eastern Cooperative Oncology Group (E3481).  Leukemia and Lymphoma.  2001; 40(3-4):357-363.

 

Xu R, Harrington DP.  A semiparametric estimate of treatment effects with censored data.  Biometrics.  2001; 57:875-885.

 

Zhao Y, Verselis SJ, Klar N, Sadowsky NL, Kaelin CM, Smith B, Foretova L, Li FP.  Nipple fluid carcinoembryonic antigen and prostate-specific antigen in cancer-bearing and tumor-free breasts.  J Clin Oncol.  2001; 19(5): 1462-1467.